NY-WEBBING
5.4.2022 14:03:04 CEST | Business Wire | Press release
Webbing , a global MVNO (Mobile Virtual Network Operator) connectivity provider for enterprise mobility and IoT, today announced the immediate availability of WebbingCTRL , a fast and simple global-ready connectivity solution. WebbingCTRL is the only SIM in the world that can easily and remotely become any wireless carrier’s SIM, eliminating network provider lock-in and providing complete control over connectivity with zero-touch provisioning.
IoT connectivity can require substantial costs and time to orchestrate the implementation of network providers. Additionally, IoT use cases are rapidly changing, so organizations need a way to make future-proof decisions today in order to handle connectivity challenges on the horizon. Using the WebbingCTRL platform, organizations can easily add, remove, and swap the carrier for any number of IoT or enterprise deployments to another wireless carrier of their choice with which they have an eSIM subscription. There’s no need for carrier integration.
The IoT environment is accelerating, and connectivity solutions need to adapt to fast-moving deployments now and in the future. The WebbingCTRL eSIM delivers total flexibility to ensure devices have reliable connectivity, anywhere in the world. The ability to remotely provision devices without extra carrier integration or collaboration also vastly reduces time-consuming deployment cycles and could have a huge impact on the ability to scale.
The WebbingCTRL solution eSIM is device agnostic and comes in any form factor. As a result, businesses can gain complete control over connectivity for a wide array of use cases, including:
- Enterprise employee mobile connectivity: Enables organizations to provide seamless connectivity for employees as they cross national boundaries and enter areas where one carrier may have better coverage than another.
- Transportation and logistics : Enable IoT tracking devices to switch automatically from a private network in a warehouse to a public network when in transit.
- Mission-critical IoT: Prevent interruption to operations that depend on connectivity when one carrier’s coverage is down by switching automatically to another.
- Automotive: Connected vehicles need constant connectivity and they cannot always use a roaming carrier due to regional connectivity regulations. WebbingCTRL can automatically change carriers as vehicles cross into new coverage areas or national borders.
“With WebbingCTRL, companies can finally take complete control of their connectivity to ensure business continuity, take advantage of better pricing and coverage and avoid having to physically touch hundreds, even thousands of devices to change carriers,” said Noam Lando, co-founder and CEO at Webbing. “Companies can securely control all their devices’ connectivity, with the confidence to connect anywhere in the world, 24-7, both now and in the future.”
Because WebbingCTRL works independently of SM-DP and SM-SR infrastructure, the carrier change takes place almost immediately, and the eSIM will act just as if the SIM card had been physically changed to the new carrier. And WebbingCTRL is not limited to public networks but can also be used to manage connectivity to private networks.
Additionally, companies can set up business rules that will automatically change the carrier under specific conditions, such as location, country, loss of connectivity or even after a certain amount of time.
For more information about WebbingCTRL and ways to streamline your IoT deployment, contact sales@iamwebbing.com .
About Webbing
Webbing is a global data MVNO that delivers innovative enterprise grade, global connectivity and IoT services. Our secured network of 600+ mobile carriers across more than 200 countries, ensures superior data connectivity between businesses, people, and things wherever the device is located.
Since our foundation in 2010, we have been developing revolutionary SIM technology, powerful management platforms and a robust global network that revolutionize your data, making it relevant and actionable. Our leading-edge solutions deliver a streamlined, centralized, and scalable means of deploying and managing organizations' global fleet of devices. Our experts assist in every step of the device on boarding process to ensure you are set up to meet your organization’s connectivity needs. For more information, visit https://www.webbingsolutions.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005430/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
